166 related articles for article (PubMed ID: 15100154)
1. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo.
Dietz AB; Souan L; Knutson GJ; Bulur PA; Litzow MR; Vuk-Pavlovic S
Blood; 2004 Aug; 104(4):1094-9. PubMed ID: 15100154
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells.
Appel S; Boehmler AM; Grünebach F; Müller MR; Rupf A; Weck MM; Hartmann U; Reichardt VL; Kanz L; Brümmendorf TH; Brossart P
Blood; 2004 Jan; 103(2):538-44. PubMed ID: 14504105
[TBL] [Abstract][Full Text] [Related]
3. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner.
Seggewiss R; Loré K; Greiner E; Magnusson MK; Price DA; Douek DC; Dunbar CE; Wiestner A
Blood; 2005 Mar; 105(6):2473-9. PubMed ID: 15572591
[TBL] [Abstract][Full Text] [Related]
4. Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro.
Cwynarski K; Laylor R; Macchiarulo E; Goldman J; Lombardi G; Melo JV; Dazzi F
Leukemia; 2004 Aug; 18(8):1332-9. PubMed ID: 15190258
[TBL] [Abstract][Full Text] [Related]
5. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation.
Matei D; Chang DD; Jeng MH
Clin Cancer Res; 2004 Jan; 10(2):681-90. PubMed ID: 14760091
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate inhibits CD4+ CD25+ regulatory T cell activity and enhances active immunotherapy against BCR-ABL- tumors.
Larmonier N; Janikashvili N; LaCasse CJ; Larmonier CB; Cantrell J; Situ E; Lundeen T; Bonnotte B; Katsanis E
J Immunol; 2008 Nov; 181(10):6955-63. PubMed ID: 18981115
[TBL] [Abstract][Full Text] [Related]
7. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
Merchant MS; Woo CW; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate, a new kid on the block for the treatment of anti-neutrophil cytoplasmic autoantibodies-associated vasculitis?
Kälsch AI; Soboletzki M; Schmitt WH; van der Woude FJ; Hochhaus A; Yard BA; Birck R
Clin Exp Immunol; 2008 Mar; 151(3):391-8. PubMed ID: 18190601
[TBL] [Abstract][Full Text] [Related]
10. An in vitro study of the cytogenetic and cytotoxic effects of imatinib mesylate, STI571 on murine erythroleukemia GM-86 cells.
Kirk MJ; Fotiadis NA; Majumdar SK
J Chemother; 2006 Feb; 18(1):49-55. PubMed ID: 16572894
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation.
Boissel N; Rousselot P; Raffoux E; Cayuela JM; Soulier J; Mooney N; Charron D; Dombret H; Toubert A; Rea D
J Leukoc Biol; 2006 Apr; 79(4):747-56. PubMed ID: 16461746
[TBL] [Abstract][Full Text] [Related]
12. Carvedilol in glioma treatment alone and with imatinib in vitro.
Erguven M; Yazihan N; Aktas E; Sabanci A; Li CJ; Oktem G; Bilir A
Int J Oncol; 2010 Apr; 36(4):857-66. PubMed ID: 20198329
[TBL] [Abstract][Full Text] [Related]
13. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
Beppu K; Jaboine J; Merchant MS; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2004 Jan; 96(1):46-55. PubMed ID: 14709738
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections.
Mumprecht S; Matter M; Pavelic V; Ochsenbein AF
Blood; 2006 Nov; 108(10):3406-13. PubMed ID: 16873671
[TBL] [Abstract][Full Text] [Related]
15. Immunocompetent cell functions in Ph+ acute lymphoblastic leukemia patients on prolonged Imatinib maintenance treatment.
Maggio R; Peragine N; De Propris MS; Vitale A; Elia L; Calabrese E; Della Starza I; Intoppa S; Milani ML; Guarini A; Foà R
Cancer Immunol Immunother; 2011 Apr; 60(4):599-607. PubMed ID: 21240485
[TBL] [Abstract][Full Text] [Related]
16. Effects of the protein kinase inhibitor, imatinib mesylate, on epithelial/mesenchymal phenotypes: implications for treatment of fibrotic diseases.
Vittal R; Zhang H; Han MK; Moore BB; Horowitz JC; Thannickal VJ
J Pharmacol Exp Ther; 2007 Apr; 321(1):35-44. PubMed ID: 17218487
[TBL] [Abstract][Full Text] [Related]
17. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
Tseng PH; Lin HP; Zhu J; Chen KF; Hade EM; Young DC; Byrd JC; Grever M; Johnson K; Druker BJ; Chen CS
Blood; 2005 May; 105(10):4021-7. PubMed ID: 15665113
[TBL] [Abstract][Full Text] [Related]
18. Slug (SNAI2) down-regulation by RNA interference facilitates apoptosis and inhibits invasive growth in neuroblastoma preclinical models.
Vitali R; Mancini C; Cesi V; Tanno B; Mancuso M; Bossi G; Zhang Y; Martinez RV; Calabretta B; Dominici C; Raschellà G
Clin Cancer Res; 2008 Jul; 14(14):4622-30. PubMed ID: 18628477
[TBL] [Abstract][Full Text] [Related]
19. A novel mechanism for imatinib mesylate (STI571) resistance in CML cell line KT-1: role of TC-PTP in modulating signals downstream from the BCR-ABL fusion protein.
Shimizu T; Miyakawa Y; Iwata S; Kuribara A; Tiganis T; Morimoto C; Ikeda Y; Kizaki M
Exp Hematol; 2004 Nov; 32(11):1057-63. PubMed ID: 15539083
[TBL] [Abstract][Full Text] [Related]
20. Wnt5a enhances the response of CML cells to Imatinib Mesylate through JNK activation and γ-catenin inhibition.
Niu CC; Zhao C; Zhang XL; Pan J; Zhao C; Wu WR; Li ZQ; Liu T; Yang Z; Si WK
Leuk Res; 2013 Nov; 37(11):1532-7. PubMed ID: 23972517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
